Expiration Date: April 1, 2017
Media: Print with online posttest, evaluation, and request for credit
This activity is designed to inform physicians about the latest advances in colorectal cancer (CRC) treatment, including current and investigational management strategies.
Instructions For This Activity & Receiving Credit
This activity is directed toward medical oncologists, gastroenterologists, primary care physicians, nurses, and nurse practitioners who treat patients with colorectal cancer. Surgical oncologists, radiation oncologists, pathologists, fellows, physician assistants, and other healthcare providers interested in the management of colorectal cancer are also invited to participate.
Learning ObjectivesAfter participating in this CME/CE activity, learners should be better prepared to:
- Discuss unmet needs in the management of relapsed metastatic CRC
- Describe the role of biomarker testing including molecular profiling in diagnosis and treatment of CRC
- Discuss and apply emerging therapies and data from recent clinical studies for the treatment of metastatic CRC
The American Journal of Hematology/ Oncology® Editorial Board
Debu Tripathy, MD
Professor of Medicine and Chair
Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Disclosure: Grant/research support from Genentech/Roche, Pfizer, Puma Biotechnology Inc, and Novartis (clinical trial support contracted to the University of Southern California and MD Anderson Cancer Center); consultant for Eisai, OncoPlex Diagnostics, Merck, and Novartis.
John Marshall, MD
Chief, Division of Hematology/Oncology
Georgetown University Hospital
Director, Ruesch Center for the Cure of GI Cancers
Disclosure: Grant/Research Support: Genentech, Amgen, Bayer, Celgene Corporation; Consultant: Genentech, Amgen, Bayer, Celgene Corporation, Indivumed Inc, Caris; Speaker's Bureau: Genentech, Amgen, Bayer, Celgene Corporation.
Staff/Planner Disclosures and Conflict of Interest Resolution
The staff of Physicians' Education Resource®, LLC, (PER®) and the editorial staff of The American Journal of Hematology/Oncology® have no relevant financial relationships with commercial interests to disclose.
It is the policy of PER® to ensure fair balance, independence, objectivity, and scientific objectivity in all of our CME activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.
Off-Label Disclosure and Disclaimer
This continuing medical and nursing education activity may or may not discuss investigational, unapproved or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only and is not meant to substitute for the independent medical judgment of a physician or nurse relative to diagnostic, treatment, and management options for a specific patient's medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians' Education Resource®, LLC. Contact information for questions about the activity:
Physicians' Education Resource®, LLC
666 Plainsboro Road, Suite 356
Plainsboro, NJ 08536
Phone: (888) 949-0045
Hardware And Software RequirementsSupported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)
Minimum System Requirements (Windows)
- A Pentium-based PC or compatible computer
- At least 64MB of RAM
- Windows 95/98/NT/ME/2000/XP/Vista system software
- Screen resolution of 1024 x 786 or larger recommended
- PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise